Ascendia

  MARKET NEWS

OrganaBio Acquires Excellos Operating Assets, Establishing a Coast-to-Coast Cell Therapy Contract Testing, Development & Manufacturing Organization
Terumo Blood & Cell Technologies & Steminent Collaborate to Advance MSC Late-Stage Clinical Manufacturing
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
Enterprise Therapeutics Achieves Primary Efficacy Outcome in Phase 2 Clinical Trial for Cystic Fibrosis With Novel Inhaled ENaC Blocker ETD001
Brainomix & Boehringer Ingelheim Advance Strategic Partnership in Pulmonary Fibrosis
ENA Respiratory Successfully Completes First Part of Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
Cereno Scientific Enters Collaboration with PHA Europe & Global to Advance Patient-centered Drug Development in Pulmonary Hypertension
Hongene Demonstrates Advanced Oligonucleotide CDMO Capabilities Through Support of SiranBio’s Dual-Target siRNA Program
Bracco Launches BubbleGen Early Access Program for Microbubble-Based Cell Selection & Activation at ISCT
Ecolab Life Sciences Opens Bioprocessing Applications Lab in Korea to Support Downstream Process Development Across Asia

  EXPERT CONTENT & RESOURCES

Incorporating Self-Administered Drug-Device Combination Products Into Clinical Trials Can Bring Outsized Challenges & Outstanding Rewards

Incorporating Self-Administered Drug-Device Combination Products Into Clinical Trials Can Bring Outsized Challenges & Outstanding Rewards

The self-administered injectable drug-device combination (DDC) product market finds itself in the beginning stages of unprecedented therapeutic advancements. And all easy pharma buzzwords aside – “revolutionary,” “breakthrough,” “dedicated expertise” – the overarching reason for this paradigm shift boils down to one word: Necessity.

Avoiding Recalls: How to Ensure Sterility in Ophthalmic Products

Avoiding Recalls: How to Ensure Sterility in Ophthalmic Products

In the wake of several high-profile eye drop recalls, we look at the challenges of achieving sterility in ophthalmic products, the consequences of failing to do so, and how AbbVie Contract Manufacturing ensures product sterility and safety.

On-Demand Presentation: Analytical Strategy & Challenges for ADC

On-Demand Presentation: Analytical Strategy & Challenges for ADC

Global Vice President of Analytical & Research Development, Scott Zugel, spoke at Veranova’s SCALE Symposium, where he outlined key analytical strategies and challenges in ADC manufacturing in the pharmaceutical industry.

  FEATURED EDITORIAL

Drug Development & Delivery

  COMPANY PROFILE

Serán BioScience, LLC is a sci­ence-based CDMO that specializes in a variety of drug delivery and formu­lation approaches suited to optimizing bioavailability. Serán’s experienced formulation team will work with you to identify an appropriate technology and formulation strategy to meet your program’s unique needs. Our comprehensive approach to formulation design considers the physiochemical properties of the API, the target product profile, and your program’s objectives and constraints to develop scalable formulations using efficient and material-sparing approaches. Click here for more.

  WHITEPAPERS & WEBINARS

WHITEPAPER - From Service Provider to Strategic Partner

WHITEPAPER - From Service Provider to Strategic Partner

By: Tom Sellig, CEO, Adare Pharma Solutions

As drug development grows more complex and timelines compress, sponsors require CDMO relationships built on integration, flexibility, and shared accountability. The relationship between pharmaceutical sponsors and their CDMO partners has undergone a fundamental …

WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

Why Early Development Requires a Different Decision Model

Early oral drug development is an exercise in working under constraint. Teams are asked to make consequential decisions when materials are limited, timelines are tight, and the data are incomplete. Traditionally, formulation …

WHITEPAPER - How Advanced Containment Technology Is Reshaping High-Potency API Micronization

WHITEPAPER - How Advanced Containment Technology Is Reshaping High-Potency API Micronization

       
By:
Harry Wade, Technical Associate, and Rosie Bird, EHS Lead, Catalent Dartford

The pharmaceutical industry faces a growing manufacturing challenge as therapeutic compounds become increasingly potent and targeted. Oncology and hormonal APIs, often designed for ultra-low dosing, promise meaningful clinical …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

May 20 – Injection Devices
May 27 – Parenteral Contract Manufacturing